<p>Inhibrx Biosciences（纳斯达克代码：INBX - 获取免费报告）于周四发布了其财报。该公司报告本季度每股收益为（$2.28），超出分析师一致预期的（$2.94）$0.66，Zacks 报道。</p>
<p>获取 <strong>Inhibrx Biosciences</strong> 的提醒：</p>
<h2>Inhibrx Biosciences 股价上涨 6.0%</h2>
<p>周五，Inhibrx Biosciences 股票上涨 $4.51，达到 $79.13。该公司的股票交易量为 600,093 股，而其平均交易量为 766,212 股。该股票的 50 日移动平均线为 $45.90，200 日移动平均线为 $27.91。Inhibrx Biosciences 的一年低点为 $10.81，一年高点为 $86.64。该股票的市值为 11.5 亿美元，市盈率为 -7.48，贝塔系数为 1.09。该公司的债务与股本比率为 1.45，速动比率为 4.98，流动比率为 4.98。</p>
<h2>华尔街分析师预测增长</h2>
<p>几家研究公司对 INBX 进行了评论。华尔街 Zen 在 8 月 17 日的报告中将 Inhibrx Biosciences 的股票评级从 “卖出” 上调至 “持有”。JMP Securities 在 8 月 22 日的研究报告中重申了对 Inhibrx Biosciences 股票的 “市场表现” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Inhibrx Biosciences 股票的 “卖出（d）” 评级。一位分析师对该股票给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，Inhibrx Biosciences 当前的平均评级为 “减持”。</p>
<p><strong>阅读我们对 INBX 的最新分析</strong></p>
<h2>Inhibrx Biosciences 的内部买卖</h2>
<p>在相关消息中，主要股东 Global Investors Lp Viking 于 10 月 7 日（星期二）出售了 350,000 股 Inhibrx Biosciences 股票。股票以平均价格 $32.25 出售，总交易额为 $11,287,500.00。交易后，内部人士在公司持有 67,018 股，价值约 $2,161,330.50。此次交易使其持股减少了 83.93%。该交易已在与 SEC 的法律文件中披露，您可以通过此链接访问。公司内部人士持有公司股票的 17.09%。</p>
<h2>Inhibrx Biosciences 的机构交易</h2>
<p>几家机构投资者和对冲基金最近买卖了 INBX 的股票。Caligan Partners LP 在第三季度购买了 Inhibrx Biosciences 的新股份，价值约 $7,961,000。SummitTX Capital L.P. 在第三季度购买了 Inhibrx Biosciences 的新股份，价值约 $1,824,000。Bridgeway Capital Management LLC 在第二季度获得了 Inhibrx Biosciences 的新头寸，价值约 $235,000。Acuta Capital Partners LLC 在第三季度购买了 Inhibrx Biosciences 的新头寸，价值约 $552,000。最后，Invesco Ltd. 在第二季度获得了 Inhibrx Biosciences 的新股份，价值约 $193,000。机构投资者和对冲基金持有公司 82.46% 的股票。</p>
<h2>Inhibrx Biosciences 公司简介</h2>
<p>（获取免费报告）</p>
<p>Inhibrx, Inc. 是一家临床阶段的生物制药公司，开发一系列新型生物治疗候选药物。该公司的治疗候选药物包括 INBRX-101，一种用于治疗 AAT 缺乏症患者的 alpha-1 抗胰蛋白酶（AAT）-Fc 融合蛋白治疗候选药物，目前正在进行 1 期临床试验。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Inhibrx Biosciences</li>
<li>股票交易：RSI 及其用途</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>如果你等着抄底，Micron Technology 可能会让你错过</li>
<li>三只超市股票证明它们仍然是必需品</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Inhibrx Biosciences 吗？</h2>
<p>在考虑 Inhibrx Biosciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Inhibrx Biosciences 并不在名单上。</p>
<p>虽然 Inhibrx Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INBX

<p>Inhibrx Biosciences（纳斯达克代码：INBX）公布了季度财报，报告每股亏损 2.28 美元，优于市场普遍预期的 2.94 美元亏损。股价上涨 6.0%，至 79.13 美元。该公司的市值为 11.5 亿美元，债务与股本比率为 1.45。分析师对该股票的评级褒贬不一。主要股东 Global Investors Lp Viking 出售了 350,000 股。机构投资者持有该公司 82.46% 的股份</p>

<p>Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) posted its earnings results on Thursday. The company reported ($2.28) EPS for the quarter, beating analysts' consensus estimates of ($2.94) by $0.66, Zacks reports.</p>
<div class="lb-trans"><p>Inhibrx Biosciences（纳斯达克代码：INBX - 获取免费报告）于周四发布了其财报。该公司报告本季度每股收益为（$2.28），超出分析师一致预期的（$2.94）$0.66，Zacks 报道。</p>
</div><p>Get <strong>Inhibrx Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Inhibrx Biosciences</strong> 的提醒：</p>
</div><h2>Inhibrx Biosciences Trading Up 6.0%</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 股价上涨 6.0%</h2>
</div><p>Inhibrx Biosciences stock traded up $4.51 during trading on Friday, hitting $79.13. The company's stock had a trading volume of 600,093 shares, compared to its average volume of 766,212. The stock's fifty day moving average is $45.90 and its 200 day moving average is $27.91. Inhibrx Biosciences has a 1-year low of $10.81 and a 1-year high of $86.64. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -7.48 and a beta of 1.09. The company has a debt-to-equity ratio of 1.45, a quick ratio of 4.98 and a current ratio of 4.98.</p>
<div class="lb-trans"><p>周五，Inhibrx Biosciences 股票上涨 $4.51，达到 $79.13。该公司的股票交易量为 600,093 股，而其平均交易量为 766,212 股。该股票的 50 日移动平均线为 $45.90，200 日移动平均线为 $27.91。Inhibrx Biosciences 的一年低点为 $10.81，一年高点为 $86.64。该股票的市值为 11.5 亿美元，市盈率为 -7.48，贝塔系数为 1.09。该公司的债务与股本比率为 1.45，速动比率为 4.98，流动比率为 4.98。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several research firms have commented on INBX. Wall Street Zen upgraded shares of Inhibrx Biosciences from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday, August 17th. JMP Securities reaffirmed a &#34;market perform&#34; rating on shares of Inhibrx Biosciences in a research report on Friday, August 22nd. Finally, Weiss Ratings reissued a &#34;sell (d)&#34; rating on shares of Inhibrx Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Inhibrx Biosciences currently has an average rating of &#34;Reduce&#34;.</p>
<div class="lb-trans"><p>几家研究公司对 INBX 进行了评论。华尔街 Zen 在 8 月 17 日的报告中将 Inhibrx Biosciences 的股票评级从 “卖出” 上调至 “持有”。JMP Securities 在 8 月 22 日的研究报告中重申了对 Inhibrx Biosciences 股票的 “市场表现” 评级。最后，Weiss Ratings 在 10 月 8 日的报告中重新发布了对 Inhibrx Biosciences 股票的 “卖出（d）” 评级。一位分析师对该股票给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，Inhibrx Biosciences 当前的平均评级为 “减持”。</p>
</div><p><strong>Read Our Latest Analysis on INBX</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 INBX 的最新分析</strong></p>
</div><h2>Insider Buying and Selling at Inhibrx Biosciences</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 的内部买卖</h2>
</div><p>In related news, major shareholder Global Investors Lp Viking sold 350,000 shares of Inhibrx Biosciences stock in a transaction on Tuesday, October 7th. The shares were sold at an average price of $32.25, for a total transaction of $11,287,500.00. Following the transaction, the insider owned 67,018 shares in the company, valued at approximately $2,161,330.50. The trade was a 83.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 17.09% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，主要股东 Global Investors Lp Viking 于 10 月 7 日（星期二）出售了 350,000 股 Inhibrx Biosciences 股票。股票以平均价格 $32.25 出售，总交易额为 $11,287,500.00。交易后，内部人士在公司持有 67,018 股，价值约 $2,161,330.50。此次交易使其持股减少了 83.93%。该交易已在与 SEC 的法律文件中披露，您可以通过此链接访问。公司内部人士持有公司股票的 17.09%。</p>
</div><h2>Institutional Trading of Inhibrx Biosciences</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 的机构交易</h2>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of INBX. Caligan Partners LP bought a new stake in shares of Inhibrx Biosciences in the 3rd quarter worth approximately $7,961,000. SummitTX Capital L.P. bought a new stake in Inhibrx Biosciences in the 3rd quarter valued at about $1,824,000. Bridgeway Capital Management LLC acquired a new position in Inhibrx Biosciences during the 2nd quarter valued at about $235,000. Acuta Capital Partners LLC bought a new position in Inhibrx Biosciences in the 3rd quarter worth about $552,000. Finally, Invesco Ltd. acquired a new stake in shares of Inhibrx Biosciences in the second quarter valued at approximately $193,000. Institutional investors and hedge funds own 82.46% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买卖了 INBX 的股票。Caligan Partners LP 在第三季度购买了 Inhibrx Biosciences 的新股份，价值约 $7,961,000。SummitTX Capital L.P. 在第三季度购买了 Inhibrx Biosciences 的新股份，价值约 $1,824,000。Bridgeway Capital Management LLC 在第二季度获得了 Inhibrx Biosciences 的新头寸，价值约 $235,000。Acuta Capital Partners LLC 在第三季度购买了 Inhibrx Biosciences 的新头寸，价值约 $552,000。最后，Invesco Ltd. 在第二季度获得了 Inhibrx Biosciences 的新股份，价值约 $193,000。机构投资者和对冲基金持有公司 82.46% 的股票。</p>
</div><h2>Inhibrx Biosciences Company Profile</h2>
<div class="lb-trans"><h2>Inhibrx Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.</p>
<div class="lb-trans"><p>Inhibrx, Inc. 是一家临床阶段的生物制药公司，开发一系列新型生物治疗候选药物。该公司的治疗候选药物包括 INBRX-101，一种用于治疗 AAT 缺乏症患者的 alpha-1 抗胰蛋白酶（AAT）-Fc 融合蛋白治疗候选药物，目前正在进行 1 期临床试验。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Inhibrx Biosciences</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>Are These 3 Oversold Tech Giants Ready to Rebound?</li>
<li>What is a buyback in stocks? A comprehensive guide for investors</li>
<li>If You Wait for the Dip, Micron Technology Could Leave You Behind</li>
<li>3 Grocery Stocks That Are Proving They Are Still Essential</li>
<li>3 Stocks Quietly Powering the AI and Tech Revolution</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Inhibrx Biosciences</li>
<li>股票交易：RSI 及其用途</li>
<li>这三只被低估的科技巨头准备反弹吗？</li>
<li>股票回购是什么？投资者的全面指南</li>
<li>如果你等着抄底，Micron Technology 可能会让你错过</li>
<li>三只超市股票证明它们仍然是必需品</li>
<li>三只悄然推动 AI 和科技革命的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5CWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=INBX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inhibrx Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Inhibrx Biosciences 吗？</h2>
</div><p>Before you consider Inhibrx Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Inhibrx Biosciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Inhibrx Biosciences 并不在名单上。</p>
</div><p>While Inhibrx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Inhibrx Biosciences 目前在分析师中被评为减持，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Inhibrx Biosciences（NASDAQ:INBX）公布财报结果